Correlation Between Zenas BioPharma, and Upstream Bio,

Can any of the company-specific risk be diversified away by investing in both Zenas BioPharma, and Upstream Bio, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Zenas BioPharma, and Upstream Bio, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Zenas BioPharma, Common and Upstream Bio,, you can compare the effects of market volatilities on Zenas BioPharma, and Upstream Bio, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Zenas BioPharma, with a short position of Upstream Bio,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Zenas BioPharma, and Upstream Bio,.

Diversification Opportunities for Zenas BioPharma, and Upstream Bio,

0.65

Correlation Coefficient

Zenas BioPharma,  Upstream Bio,

Poor diversification

The 3 months correlation between Zenas and Upstream is 0.65. Overlapping area represents the amount of risk that can be diversified away by holding Zenas BioPharma, Common and Upstream Bio, in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Upstream Bio, and Zenas BioPharma, is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Zenas BioPharma, Common are associated (or correlated) with Upstream Bio,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Upstream Bio, has no effect on the direction of Zenas BioPharma, i.e., Zenas BioPharma, and Upstream Bio, go up and down completely randomly.

Pair Corralation between Zenas BioPharma, and Upstream Bio,

Given the investment horizon of 90 days Zenas BioPharma, Common is expected to under-perform the Upstream Bio,. But the etf apears to be less risky and, when comparing its historical volatility, Zenas BioPharma, Common is 1.16 times less risky than Upstream Bio,. The etf trades about -0.11 of its potential returns per unit of risk. The Upstream Bio, is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest  1,700  in Upstream Bio, on September 28, 2024 and sell it today you would earn a total of  245.00  from holding Upstream Bio, or generate 14.41% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	87.1%
Values	Daily Returns

Zenas BioPharma, Common  vs.  Upstream Bio,

Zenas BioPharma, Common

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

Upstream Bio,

Risk-Adjusted Performance

5 of 100

Modest

Compared to the overall equity markets, risk-adjusted returns on investments in Upstream Bio, are ranked lower than 5 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Upstream Bio, sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Zenas BioPharma, and Upstream Bio,

The main advantage of trading using opposite Zenas BioPharma, and Upstream Bio, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Zenas BioPharma, position performs unexpectedly, Upstream Bio, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Upstream Bio, will offset losses from the drop in Upstream Bio,'s long position.

The idea behind Zenas BioPharma, Common and Upstream Bio, pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.